WHOLE-BODY POSITRON EMISSION TOMOGRAPHY IN BREAST-CANCER

被引：8

作者：

NITZSCHE, EU

HOH, CK

DALBOHM, NM

GLASPY, JA

PHELPS, ME

MOSER, EA

HAWKINS, RA

机构：

[1] UNIV FREIBURG, ZENTRUM MED RADIOL, NUKL MED ABT, W-7800 FREIBURG, GERMANY

[2] UNIV CALIF LOS ANGELES, SCH MED, DEPT RADIOL SCI, DIV NUCL MED & BIOPHYS, LOS ANGELES, CA USA

来源：

FORTSCHRITTE AUF DEM GEBIETE DER RONTGENSTRAHLEN UND DER NEUEN BILDGEBENDEN VERFAHREN | 1993年 / 158卷 / 04期

关键词：

FDG-PET; BREAST CANCER; WHOLE BODY PET; CANCER IMAGING;

D O I：

10.1055/s-2008-1032653

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The value of whole body positron emission tomography using F-18 2-deoxy-2-fluoro-d-glucose in primary work-up and follow-up was prospectively evaluated in 37 patients with primary or metastatic breast cancer. From 20 primary breast masses 15 from 16 malignant and 4 from 4 benign lesions confirmed by biopsy, were detected. In 3 out of 21 patients in correlation to morphologic imaging, respectively biopsy, no metastatic disease was not identified. Generally speaking, whole body positron emission tomography appears to be a suitable diagnostic staging tool in breast cancer.

引用

页码：293 / 298

页数：6

共 22 条

[1]

DAHL J, 1991, J AM COLL CARDIOL, V17, pA121

[2]

GUTOWSKI TD, 1992, J NUCL MED, V33, pA925

[3]

HABERKORN U, 1991, J NUCL MED, V32, P1548

[4]

HARRIS JR, 1991, CANCER PRINCIPLES PR, P1206